Direct high-speed alphanumeric printing system for labware,
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Food and Drug Administration (FDA) is seeking quotes for a Direct High-Speed Alphanumeric Printing System for Labware. This Solicitation (RFQ) is a Total Small Business Set-Aside under NAICS 334118. The system will enable direct printing on laboratory tubes and vials, eliminating adhesive labels that fail in extreme conditions. Quotes are due May 8, 2026, by 2:00 PM Central Time.
Scope of Work
The FDA requires one (1) stand-alone, high-throughput system capable of directly printing alphanumeric labels on various labware (1.5 mL to 50 mL conical tubes, 96-well plates). Key requirements include:
- Direct-to-media printing: No reliance on adhesive labels.
- Extreme environment resistance: Labels must withstand temperatures from -80°C to -160°C and resist smearing from water or alcohol.
- Physical specifications: System dimensions less than 40"w x 20"l, 100-240V AC power.
- Support & Training: Includes a one-year ink subscription, one-year warranty with on-site preventive maintenance, software updates, parts/labor, inside delivery, installation, and FDA end-user training.
- Post-acceptance support: One-year warranty from FDA acceptance for troubleshooting, parts, and updates, plus a minimum of two years of phone and email technical support.
- Compliance: Components must be newly manufactured, and ICT supplies must comply with Section 508 accessibility standards (ACR required).
Contract Details
- Contract Type: Firm-Fixed-Price.
- Set-Aside: Total Small Business (NAICS 334118, Size Standard: 1,000 employees).
- Place of Delivery: U.S. FDA Center for Biologics Evaluation and Research (CBER), Silver Spring, MD.
- Period of Performance: Offerors must hold prices firm through September 30, 2026.
Submission & Evaluation
- Submission Deadline: Friday, May 8, 2026, by 2:00 PM Central Time.
- Submission Method: Email only to timothy.walbert@fda.hhs.gov. No .exe, .mso, or other executable file types.
- Evaluation: Award will be made to the responsible Offeror whose offer is most advantageous to the Government, based on Lowest Price Technically Acceptable (LPTA).
- Technical Acceptability: Determined by review of submitted descriptive material, literature, and brochures.
- Price: Must be detailed and respond to the schedule of supplies/services.
- Eligibility: Offerors must be registered and active in SAM.gov by the quote receipt deadline.
Additional Notes
This is a combined synopsis-solicitation (RFQ). Full text of incorporated FAR and HHSAR clauses can be accessed via the provided acquisition.gov and hhs.gov links. Payment terms are Net 30 days, with electronic invoicing via the Invoice Processing Platform (IPP).